ST-503 / Sangamo Therap - LARVOL DELTA

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy (GlobeNewswire) - "Sangamo expects to dose the first Phase 1/2 STAND study patient in the coming months."

Fast track • Trial status • Pain

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Sangamo Therapeutics | Phase classification: P1 ➔ P1/2

Phase classification • Gene Therapies • Neuralgia • Pain • Peripheral Neuropathic Pain

Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Sangamo Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gene Therapies • Neuralgia • Pain

Preclinical development of ST-503: an investigational adeno-associated viral vector-delivered zinc finger repressor novel epigenetic therapy for idiopathic small fiber neuropathy (NeuPSIG 2025) - "Collectively, these results demonstrate potency, specificity, efficacy, and safety of ST-503 and support its clinical development for treatment of iSFN. The ST-503 Phase 1 clinical study in iSFN patients will be initiated in 2025."

Preclinical • Viral vector • CNS Disorders • Neuralgia • Pain • NAV1

Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Sangamo Therapeutics | Initiation date: Jul 2025 ➔ Oct 2025

Trial initiation date • Gene Therapies • Neuralgia • Pain

AAV-mediated Delivery of an Engineered Zinc Finger Lead to Selective and Potent Repression of Nav1.7 in Human Sensory Neurons and Nonhuman Primates DRG Nociceptors Following Intrathecal Injection (ASGCT 2025) - "The results demonstrate the potency and selectivity of a AAV-ZFR in NHPs and support further development of ST-503, an investigational therapy for the treatment of intractable pain due to iSFN. Disease Focus of Abstract:Peripheral Nervous System Disorders"

Neuralgia • Pain • NAV1 • SCN8A

Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Sangamo Therapeutics

New P1 trial • Gene Therapies • Neuralgia • Pain

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Businesswire) - "Sangamo Therapeutics...today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format....These presentations describe the profound survival benefits of the treatment in disease mouse models, and the sustained, brain-wide suppression of prion protein expression in both mouse and nonhuman primate models, supporting its potential as a one-time therapeutic approach for prion disease. The third presentation focuses on the advancement of ST-503, a ZFR targeting the gene encoding Nav1.7, for the treatment of intractable, chronic neuropathic pain following intrathecal delivery."

Preclinical • CNS Disorders • Neuralgia

Antibiotic Resistance and Virulence Determinants of Pseudomonas aeruginosa Isolates Cultured from Hydrocarbon-Contaminated Environmental Samples. (PubMed, Microorganisms) - "Several P. aeruginosa sequence types that were associated with oil-contaminated environments have also been cultured from human clinical samples worldwide, including sequence types ST532, ST267, ST244, and ST1503. Our findings also indicate that environmental P. aeruginosa may serve as the source of human infections, warranting further studies from a One Health perspective about the application of P. aeruginosa for the in situ bioremediation of hydrocarbon-contaminated sites."

Journal • Infectious Disease

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (Businesswire) - "Chronic Neuropathic Pain - ST-503: (i) IND application cleared by the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain; (ii) Preparing for a Phase 1/2 study of ST-503 to assess the safety, tolerability and preliminary efficacy of a one-time dose administered intrathecally to patients with intractable pain due to iSFN; (iii) Expect to commence patient enrollment and dosing in mid-2025, with preliminary proof of efficacy data anticipated in Q4 2026."

IND • New P1/2 trial • Pain